[A phase II study of SM-5887 for advanced gastric cancer].
A phase II clinical trial of SM-5887, a new totally synthesized anthracycline derivative, was carried out in 13 patients with inoperable or recurrent gastric cancer. No patient had been given anthracycline previously. SM-5887 was administered by I.V. bolus with a dose of 100 mg/m2 every three weeks. Twelve of 13 cases were eligible and evaluable for the response. Of the 12 evaluated cases, 6 showed no change (NC), including one minor response (MR). The remaining 6 cases showed progressive disease (PD). Adverse effects were relatively mild in most cases and included anemia, leukocytopenia, thrombocytopenia, nausea/vomiting, phlebitis, hair loss and fever. Among them, leukocytopenia was observed most frequently.
Tsushima
K
K
First Dep. of Internal Medicine, Hirosaki University School of Medicine.
Sakata
Y
Y
Munakata
A
A
Sato
T
T
Chiba
Y
Y
Nara
H
H
Kawazu
S
S
Matsukawa
M
M
Ohmi
T
T
Aizawa
T
T
D000230:Adenocarcinoma / Q000188:drug therapy; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy; D000231:Adenocarcinoma, Papillary / Q000188:drug therapy; D000328:Adult; D000368:Aged; D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000188:drug therapy*
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; C055866:amrubicin